Navigation Links
AutoImmune Inc. Reports 2009 Second Quarter Financial Results
Date:8/6/2009

re no statistically significant differences between dirucotide and placebo on the secondary endpoints of the study. Eli Lilly and BioMS also announced that they would discontinue ongoing clinical trials and review available data. Chairman of the Board and Chief Executive Officer Robert C. Bishop, Ph.D. stated, "We are obviously disappointed by the results and look forward to further announcements from BioMS and Lilly regarding their future plans for this approach to treating SPMS."

AutoImmune is a biopharmaceutical company involved in the development of treatments for autoimmune and cell-mediated inflammatory diseases and conditions.

Statements in this release that are not strictly historical are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These statements include statements about clinical trials and studies and future sales, royalties and revenue. You can identify these forward-looking statements because they involve our expectations, beliefs, projections, anticipations or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to the uncertainties of clinical trial results, AutoImmune's dependence on third parties for licensing revenue, and the risks of technological change and competition. These factors are more fully discussed, as are other factors, in AutoImmune's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission in the section entitled "Risk Factors." We have no plans, and disclaim any obligation, to update or revise any forward-looking statements whether as a result of new information, future events
'/>"/>

SOURCE AutoImmune Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AutoImmune Inc. Reports 2009 First Quarter Financial Results
2. AutoImmune Inc. Reports 2008 Fourth Quarter and Year End Financial Results
3. Advances in Detection Technology Drive the European Autoimmune Disease Diagnostics Market
4. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
5. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
6. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
7. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
8. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
9. Synthetech Reports First Quarter Fiscal 2010 Results
10. GenVec Reports Second Quarter 2009 Financial Results
11. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... BOSTON , Jan. 22, 2015  Transwestern | RBJ today ... feet of office space for Shire a leading biopharmaceutical company, ... . Transwestern | RBJ,s Robert Richards , president, and ... the lease for the entire five-floor building at 95 Hayden ...
(Date:1/22/2015)... CAMBRIDGE, Mass (PRWEB) January 21, 2015 Cambridge ... Semantic Web technology, today announced that 2014 was a record-breaking ... expanding the capabilities of the Anzo Smart Data Platform and ... discover and utilize insights from diverse data which led to ...
(Date:1/22/2015)... Boulder, CO / Rootstown, OH (PRWEB) January 22, 2015 ... sensitive detection platform, announced today that it has received AOAC-PTM ... O26, O45, O1O3, O111, O121, and O145; collectively referred to ... (E. coli) O157, at 1 colony forming unit (cfu) per ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was invited to ... on probiotics in San Diego, CA. , The Scripps ... health care professionals. This year’s pre-conference seminar was held on ... Dr. Leyer spoke about the emerging topics and science in ...
Breaking Biology Technology:Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Cambridge Semantics Announces Record Results for 2014 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2
... ICON plc, (NASDAQ:, ICLR ; ISIN:IE0005711209), ... pharmaceutical, biotechnology and medical device industries,today announced the ... accelerate,the adjudication of cardiovascular events in diabetes studies. ... cardiovascular risk in diabetic trials has been the,subject ...
... Cell Therapeutics (CTI),(Nasdaq and MTA: CTIC) announced today ... Shareholders on February 27, 2009 in lieu of the ... on February 6, 2009.,Shareholders of record at the close ... by the Board of Directors, will be entitled to ...
... Austria, Jan. 23 Intercell AG,(VSE: ICLL) today ... product approval for the company,s vaccine to,prevent Japanese ... vaccine,follows the positive recommendation provided by Australian Drug ... This decision of the Australian authorities ...
Cached Biology Technology:ICON Delivers New Electronic Solution to Expedite Clinical Trial Adjudication 2ICON Delivers New Electronic Solution to Expedite Clinical Trial Adjudication 3Australian Authorities (TGA) First to Grant Final Product Approval for Intercell's Vaccine to Prevent Japanese Encephalitis 2Australian Authorities (TGA) First to Grant Final Product Approval for Intercell's Vaccine to Prevent Japanese Encephalitis 3Australian Authorities (TGA) First to Grant Final Product Approval for Intercell's Vaccine to Prevent Japanese Encephalitis 4
(Date:1/22/2015)... 2015 , Europe,s ... The European Patent Office to present a video retrospective of the ... be featured: Christofer Toumazou and Sophie Wilson   ... winners of the Award   Starting on 22 January ...
(Date:1/22/2015)... Jan. 22, 2015 Infinisource has launched its new NXG ... model. The G2 sets a higher standard for collecting attendance ... management solution. With plug-and-play installation, touch screen interface and seamless ... a robust time collection solution for the small to mid-size ...
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides ... and fingerprinting markets. Watermarking aims to control and ...
Breaking Biology News(10 mins):Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3Infinisource's NXG series sets new time clock standard 2The Global Watermarking and Fingerprinting Markets 2
... 2010) -- The cover story of the most recent ... University of Miami (UM) led expedition to the underwater ... These unique environments are one of the least understood ... involved in studying these extreme environments, which include complete ...
... 2010) The term "macrophage" conjures images of a ... do much more than that: Not only do they ... in immune regulation and wound-healing. They can respond to ... in response to local cues. David Mosser, Professor ...
... A new study of the genetic basis of circadian ... has found that a few minutes of light exposure ... biological functions, everything from reproduction to coloring and DNA repair. ... fungus were known to be responsible for gene activation by ...
Cached Biology News:National Geographic features University of Miami's work on Bahamas 'blue holes' 2National Geographic features University of Miami's work on Bahamas 'blue holes' 3Macrophages: The 'defense' cells that help throughout the body 2Macrophages: The 'defense' cells that help throughout the body 3Light, circadian rhythms affect vast range of physiological, behavioral functions 2